Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05EUR
|
|||
| Drug Name |
LJN452
|
|||
| Synonyms |
Tropifexor; 1383816-29-2; UNII-NMZ08KM76Z; NMZ08KM76Z; CPD1549; Tropifexor [INN]; GTPL9725; SCHEMBL19178329; SCHEMBL17848159; LJN-452; EX-A1934; CS-8153; compound 1 [PMID: 29148806]; ACN-053193; AC-30341; 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid; HY-107418; 2-((1R,5S)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorob
Click to Show/Hide
|
|||
| Indication | Primary biliary cholangitis [ICD-11: DB96.1] | Phase 2 | [1] | |
| Company |
Novartis Pharmaceuticals East Hanover, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H25F4N3O5S
|
|||
| Canonical SMILES |
C1CC1C2=C(C(=NO2)C3=CC=CC=C3OC(F)(F)F)COC4CC5CCC(C4)N5C6=NC7=C(C=C(C=C7S6)C(=O)O)F
|
|||
| InChI |
1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)/t16-,17+,18?
|
|||
| InChIKey |
VYLOOGHLKSNNEK-JWTNVVGKSA-N
|
|||
| CAS Number |
CAS 1383816-29-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [1], [2] |
| KEGG Pathway | Bile secretion | |||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Recycling of bile acids and salts | |||
| PPARA activates gene expression | ||||
| Endogenous sterols | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| Farnesoid X Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.